Research Analysts Set Expectations for Hologic Q1 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Equities research analysts at Zacks Research boosted their Q1 2026 earnings estimates for shares of Hologic in a report issued on Monday, November 24th. Zacks Research analyst Team now anticipates that the medical equipment provider will earn $1.07 per share for the quarter, up from their previous estimate of $1.06. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q2 2026 earnings at $1.08 EPS, FY2026 earnings at $4.45 EPS, Q1 2027 earnings at $1.20 EPS, Q2 2027 earnings at $1.26 EPS, FY2027 earnings at $4.92 EPS and FY2028 earnings at $5.35 EPS.

Other equities research analysts have also issued reports about the stock. BNP Paribas Exane lowered shares of Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 price objective for the company. in a report on Friday, November 21st. Raymond James Financial lowered shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Mizuho downgraded shares of Hologic from an “outperform” rating to a “neutral” rating and lifted their price target for the company from $70.00 to $78.00 in a report on Thursday, October 23rd. Wall Street Zen cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Finally, Leerink Partners raised their price objective on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a research report on Tuesday, October 21st. Five investment analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $79.67.

Hologic Stock Down 0.1%

Shares of HOLX opened at $74.80 on Wednesday. The business’s 50 day moving average is $71.17 and its 200 day moving average is $66.79. The company has a market capitalization of $16.67 billion, a PE ratio of 31.04, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. Hologic has a 12-month low of $51.90 and a 12-month high of $80.31. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. During the same period last year, the firm earned $1.01 earnings per share. The business’s quarterly revenue was up 6.2% on a year-over-year basis.

Insider Activity

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.88% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hologic

Several hedge funds have recently bought and sold shares of HOLX. United Services Automobile Association purchased a new position in shares of Hologic during the first quarter worth approximately $347,000. K.J. Harrison & Partners Inc bought a new position in Hologic in the second quarter worth approximately $1,987,000. Aberdeen Group plc increased its holdings in Hologic by 2.8% during the 2nd quarter. Aberdeen Group plc now owns 244,997 shares of the medical equipment provider’s stock worth $15,964,000 after purchasing an additional 6,589 shares during the period. Nordea Investment Management AB raised its position in Hologic by 7.2% during the 2nd quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider’s stock valued at $168,674,000 after purchasing an additional 174,828 shares in the last quarter. Finally, Carnegie Investment Counsel lifted its holdings in shares of Hologic by 10.6% in the 2nd quarter. Carnegie Investment Counsel now owns 221,528 shares of the medical equipment provider’s stock worth $14,435,000 after buying an additional 21,273 shares during the period. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.